NCT01196026View on ClinicalTrials.gov

Immunogenicity and Safety Study of Fluarix™ Vaccine in Children Who Have Previously Been Vaccinated With Pandemrix™

PHASE4CompletedINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

September 15, 2010

Primary Completion Date

May 26, 2011

Study Completion Date

May 26, 2011

Conditions
Influenza
Interventions
BIOLOGICAL

Fluarix™

One or two intramuscular injections

BIOLOGICAL

Havrix™ Junior

Two intramuscular injections

Trial Locations (7)

3011 EN

GSK Investigational Site, Rotterdam

SE-371 41

GSK Investigational Site, Karlskrona

SE-205 02

GSK Investigational Site, Malmo

SE-702 11

GSK Investigational Site, Örebro

SE-931 86

GSK Investigational Site, Skellefteå

SE-118 83

GSK Investigational Site, Stockholm

SE-901 85

GSK Investigational Site, Umeå

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01196026 - Immunogenicity and Safety Study of Fluarix™ Vaccine in Children Who Have Previously Been Vaccinated With Pandemrix™ | Biotech Hunter | Biotech Hunter